Measurements of endogenous levels of EPO in CSF of patients with neurodegenerative diseases has revealed EPO in CSF of patients with ALS to be lower than in controls whereas patients with Alzheimer disease (AD) or vascular dementia had EPO levels comparable to control persons [163,164]. Here, EPO is linked to Alzheimer disease.